By Dr Pranab Gyawali, Consultant Gastroenterologist (UK-trained) in Dubai
Why this study matters
Choosing the right biologic treatment in Crohn’s disease is one of the most important decisions we make in clinic. Direct comparisons between biologics are rare and provide useful insight.
What was studied
The SEQUENCE trial followed patients over 48 weeks. These were patients who had already failed anti-TNF therapy such as infliximab.
What were the results
- Skyrizi endoscopic remission ~32 percent
- Stelara endoscopic remission ~16 percent
How I use this in clinic
The way I think about this in clinic is simple. If a treatment is already working, that response is valuable information about the individual patient.
The mistake I often see is assuming everyone should switch based on a study. That is not how Crohn’s care works.
What matters most
Choosing the right treatment for each individual patient to achieve deep healing.
Learn about Biologicals used in UC and Crohn’s in Dubai Biologics for IBD in Dubai
Recommended Guides
IBD Related Topics
- Gut Microbiome
- Diet and Microbiome
- IBD Treatment Update
- Leaky Gut
- SIBO
- Iron Deficiency
- Vitamin D
- Probiotics
- Diet in Crohn’s
- Plant-Based Diet
- Ultra-Processed Foods
- Stress and Gut Brain Axis
Investigations & Procedures
If you wish to discuss this further or would like to make an appointment, please use the booking form on this page. A member of our team will contact you within 12 business hours.